SVN53-67/M57-KLH peptide vaccine

Drug Profile

SVN53-67/M57-KLH peptide vaccine

Alternative Names: SurVaxM; Survivin peptide mimic vaccine - MimiVax; Survivin-targeted peptide vaccine - MimiVax

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action BIRC5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Multiple myeloma
  • No development reported Glioma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Combination therapy) in USA (SC, Injection)
  • 01 Jun 2016 Roswell Park Cancer Institute plans a clinical trial for Multiple myeloma (Combination therapy)
  • 15 Mar 2016 Phase-I clinical trials in Multiple myeloma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top